Kilic_2024_Drug.Dev.Res_85_e22183

One of the worst long-term health issues of the past few decades is Alzheimer's disease (AD). Unfortunately, there are currently insufficient choices for treating and caring for AD, which makes it a popular subject for drug development research. Studies on the development of drugs for AD have primarily concentrated on the use of multitarget directed ligands. Following this strategy, we designed new ChE inhibitors with additional antioxidant and metal chelator effects. In this research, eight novel N'-(quinolin-4-ylmethylene)propanehydrazide derivatives were synthesized and characterized. We then evaluated the inhibition potency of all the final compounds for cholinesterase enzymes. Among them, 4e (IC(50) acetylcholinesterase [AChE] = 0.69 microM and butyrylcholinesterase [BChE]= 26.00 microM) and 4h (IC(50')s AChE= 7.04 microM and BChE= 16.06 microM) were found to be the most potent AChE and BChE inhibitors, respectively.